According to Gram Research analysis, people established on immune-suppressing drugs for conditions like rheumatoid arthritis don’t need blood tests every three months, a 2026 comprehensive study found that serious side effects are uncommon after initial treatment, and testing intervals can safely extend to 6-12 months based on individual risk factors. Researchers developed prediction calculators using readily available patient information that accurately identified who needed closer monitoring, and both patients and doctors found longer testing intervals acceptable and cost-effective.
A major 2026 research study found that people taking immune-suppressing medications for conditions like rheumatoid arthritis and psoriasis may not need blood tests every three months. Researchers analyzed data from thousands of patients and discovered that serious side effects are actually quite rare once treatment is established. By using a personalized risk calculator, doctors could safely space out blood tests to every 6-12 months for many patients, saving money and reducing unnecessary clinic visits. Both patients and doctors agreed this approach was acceptable and practical.
Key Statistics
A 2026 mixed-methods study analyzing thousands of UK patients found that clinically significant side effects from immune-suppressing drugs are uncommon during long-term treatment, with five validated prediction models achieving excellent performance characteristics for identifying high-risk patients.
Health economic modeling in the 2026 study demonstrated that extending blood test intervals from 3-monthly to 6-12 months for established patients was cost-effective, with savings from fewer tests outweighing the small risk of occasionally missing a problem.
In interviews with 18 patients and 13 healthcare professionals, the 2026 research found strong acceptance for increasing monitoring intervals from 3-monthly to 6-monthly or annually depending on individual risk profiles.
The prediction models developed in the 2026 study showed calibration slopes of 0.94 for methotrexate, 1.10 for thiopurines, and 0.91 for leflunomide, indicating excellent accuracy in identifying which patients would develop serious side effects.
The Quick Take
- What they studied: Whether people on immune-suppressing drugs need blood tests every three months, or if longer intervals between tests are safe and cost-effective.
- Who participated: Thousands of patients in the UK taking immune-suppressing medications for inflammatory conditions like rheumatoid arthritis, psoriasis, and inflammatory bowel disease, plus interviews with 18 patients and 13 healthcare professionals.
- Key finding: Serious side effects from these medications are uncommon after the first few months of treatment, and blood tests can safely be spaced out to 6-12 months depending on individual risk factors, saving healthcare costs without compromising safety.
- What it means for you: If you’re on immune-suppressing drugs and stable, you may be able to reduce how often you get blood tests, meaning fewer clinic visits and less time away from work or home. However, your doctor should assess your individual risk before making changes.
The Research Details
This was a comprehensive mixed-methods study combining multiple research approaches. First, researchers reviewed all published studies about blood test monitoring strategies for patients on immune-suppressing drugs. They then analyzed real patient data from UK medical records to identify which patients developed serious side effects and what factors predicted these problems. Using this information, they created five prediction calculators to estimate individual risk. Finally, they interviewed patients and doctors to understand their experiences and whether they’d accept longer intervals between blood tests.
The study examined five commonly used immune-suppressing medications: methotrexate, thiopurines, leflunomide, sulfasalazine, and 5-aminosalicylates. Researchers looked for three types of side effects: problems with blood cell counts, liver damage, and kidney damage. They compared the costs of frequent testing versus less frequent testing, accounting for the small risk of missing a problem.
Current practice requires all patients on these medications to have blood tests every three months, even though serious side effects become rare after the first few months of treatment. This approach wastes healthcare resources and burdens patients with unnecessary appointments. By using personalized risk assessment, doctors could target monitoring to those who actually need it, making the healthcare system more efficient while maintaining safety.
This study is high-quality because it combined multiple research methods (systematic review, data analysis, economic modeling, and patient interviews). The prediction models performed excellently when tested on new patient data. The research used real patient information from established UK medical databases rather than relying only on published studies. Importantly, both patients and healthcare professionals agreed the findings were practical and acceptable, which increases the likelihood they’ll be adopted in real-world practice.
What the Results Show
Researchers found that serious side effects from immune-suppressing drugs are uncommon once patients have been on treatment for several months. The most important discovery was that certain readily available information could predict which patients were at higher risk. For example, patients with elevated liver enzymes at the start of methotrexate treatment were more likely to develop liver problems, as were those not taking folic acid supplements.
The study developed five prediction calculators that accurately identified high-risk patients. These calculators used simple information doctors already collect, like baseline liver function tests and which medication the patient was taking. When tested on new patients, these calculators worked very well, correctly identifying who would and wouldn’t develop problems.
Health economic analysis showed that spacing out blood tests to 6-12 months (instead of every 3 months) would save money without causing significant harm. The savings from fewer tests outweighed the small risk of occasionally missing a problem. For some medications like leflunomide, testing every two years was cost-effective for low-risk patients.
Interviews with 18 patients and 13 healthcare professionals revealed strong acceptance of longer testing intervals. Patients appreciated fewer clinic visits and less disruption to their lives. Healthcare professionals found the personalized risk approach practical and aligned with their clinical judgment. Both groups felt that moving from 3-monthly to 6-monthly or annual testing was reasonable, especially for patients at low risk.
Previous research showed inconsistency in how often different doctors monitored patients, with no clear evidence supporting the standard 3-monthly interval. This study provides the first comprehensive evidence-based framework for personalizing monitoring. It confirms what many clinicians suspected: that one-size-fits-all monitoring is inefficient and that risk-based approaches are both safer and more cost-effective.
The study couldn’t combine results from all published studies because different researchers used different testing schedules and defined side effects differently. The prediction models for two medications (anti-TNF drugs and mycophenolate) couldn’t be developed because serious side effects were too rare to study. The research focused on UK patients, so results may need adjustment for other countries with different healthcare systems or patient populations. Finally, while the study shows longer intervals are acceptable, actual implementation in clinical practice will require additional testing to ensure real-world effectiveness.
The Bottom Line
For patients established on immune-suppressing drugs (beyond the first 3-6 months of treatment), blood tests can be safely spaced out based on individual risk factors. Low-risk patients may need testing only annually, while higher-risk patients might need 6-monthly tests. This should be determined using a personalized risk assessment with your doctor. High confidence: This recommendation is based on strong evidence from large patient databases and was validated on new patient data.
This research is most relevant for adults with inflammatory conditions (rheumatoid arthritis, psoriasis, inflammatory bowel disease) who are stable on immune-suppressing medications. It’s less relevant for patients newly starting these drugs, who still need frequent monitoring. Patients should discuss personalized monitoring intervals with their rheumatologist or gastroenterologist.
If your doctor adjusts your monitoring schedule, you should see benefits immediately: fewer clinic visits, less time off work, and reduced anxiety about frequent testing. Safety is maintained because the longer intervals are based on your individual risk profile. Any changes should be gradual and discussed with your healthcare team.
Frequently Asked Questions
How often should I get blood tests if I’m on methotrexate for rheumatoid arthritis?
A 2026 study found that after the first few months of treatment, blood tests can be spaced to 6-12 months depending on your individual risk factors. Your doctor should assess whether you have risk factors like elevated liver enzymes or lack of folic acid supplementation, which would require more frequent monitoring.
Are blood tests every 3 months really necessary for immune-suppressing drugs?
Research shows serious side effects become uncommon after initial treatment, making 3-monthly testing unnecessary for many stable patients. A 2026 study found that personalized risk-based intervals (6-12 months for low-risk patients) were equally safe and more cost-effective than routine 3-monthly testing.
What factors determine if I need more frequent blood tests on these medications?
The 2026 study identified specific risk factors including elevated liver enzymes at baseline, not taking folic acid supplements (for methotrexate), and certain genetic variations. Your doctor can use these factors to determine your personalized testing interval rather than using a one-size-fits-all approach.
Will I miss serious side effects if I get blood tests less often?
A 2026 comprehensive study found that serious side effects are rare during long-term treatment and can be predicted using readily available information. Personalized risk calculators accurately identified high-risk patients, and longer testing intervals were acceptable to both patients and doctors without compromising safety.
Can I reduce my blood test frequency if I’ve been stable on my medication for years?
Research shows that patients established on immune-suppressing drugs for extended periods can safely have longer intervals between blood tests. A 2026 study found that 6-12 month intervals were cost-effective for many stable patients, though your specific interval should be determined by your doctor based on your individual risk profile.
Want to Apply This Research?
- Track your blood test dates and results (liver enzymes, kidney function, blood counts) in the app. Set reminders for when your next test is due based on your personalized interval. Log any new symptoms between tests to discuss with your doctor.
- Work with your doctor to establish a personalized testing schedule based on your risk profile. Instead of automatically scheduling 3-monthly appointments, use the app to track when you’re actually due for testing. This reduces unnecessary clinic visits while maintaining safety.
- Create a long-term tracking dashboard showing your test results over time. This helps you and your doctor identify trends (like gradually rising liver enzymes) that might warrant more frequent testing. Share this data during appointments to support discussions about adjusting your monitoring interval.
This research provides evidence-based guidance for monitoring patients on immune-suppressing medications, but individual monitoring schedules should be determined by your healthcare provider based on your specific medical history, risk factors, and clinical circumstances. Do not change your blood test schedule without consulting your doctor. This information is for educational purposes and should not replace professional medical advice. If you experience symptoms like unusual bruising, jaundice, or changes in urination while on these medications, contact your healthcare provider immediately regardless of your scheduled test date.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.
